Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature

Jennette, 2013, 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Arthritis Rheum, 65, 1, 10.1002/art.37715 Fries, 1990, The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary, Arthritis Rheum, 33, 1135, 10.1002/art.1780330812 Jain, 2000, Takayasu arteritis in children and young indians, Int J Cardiol, 75, S153, 10.1016/S0167-5273(00)00180-7 Arend, 1990, The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis, Arthritis Rheum, 33, 1129, 10.1002/art.1780330811 Kerr, 1994, Takayasu arteritis, Ann Int Med, 120, 919, 10.7326/0003-4819-120-11-199406010-00004 Singh, 2013, Takayasu arteritis in infancy, Rheumatology (Oxford), 52, 2093, 10.1093/rheumatology/ket109 Ozen, 2007, Childhood vasculitides in Turkey: a nationwide survey, Clin Rheumatol, 26, 196 Unizony, 2013, New treatment strategies in large-vessel vasculitis, Curr Opin Rheumatol, 25, 3, 10.1097/BOR.0b013e32835b133a Misra, 2013, Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010), Rheumatology (Oxford), 52, 1795, 10.1093/rheumatology/ket128 Arnaud, 2011, Pathogenesis of Takayasu’s arteritis: a 2011 update, Autoimmun Rev, 11, 61, 10.1016/j.autrev.2011.08.001 Park, 2006, Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis, Rheumatology (Oxford), 45, 545, 10.1093/rheumatology/kei266 Nishimoto, 2006, Interleukin 6: from bench to bedside, Nat Clin Pract Rheumatol, 2, 619, 10.1038/ncprheum0338 Tombetti, 2014, Anti-cytokine treatment for Takayasu arteritis: state of the art, Intractable Rare Dis Res, 3, 29, 10.5582/irdr.3.29 Arnaud, 2010, Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and Black patients, Medicine (Baltimore), 89, 1, 10.1097/MD.0b013e3181cba0a3 Tombetti, 2013, Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center, J Rheumatol, 40, 2047, 10.3899/jrheum.130536 Ozen, 2007, Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate, J Pediatr, 150, 72, 10.1016/j.jpeds.2006.10.059 Abisror, 2013, Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review, Autoimmun Rev, 12, 1143, 10.1016/j.autrev.2013.06.019 Nakaoka, 2013, Tocilizumab for the treatment of patients with refractory Takayasu arteritis, Int Heart J, 54, 405, 10.1536/ihj.54.405 Osman, 2015, Tocilizumab for treating Takayasu’s arteritis and associated stroke: a case series and updated review of the literature, J Stroke Cerebrovasc Dis, 24, 1291, 10.1016/j.jstrokecerebrovasdis.2015.01.032 Ozen, 2010, EULAR/PRINTO/PRES criteria for Henoch–Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria, Ann Rheum Dis, 69, 798, 10.1136/ard.2009.116657 Bravo Mancheno, 2012, Successful tocilizumab treatment in a child with refractory Takayasu arteritis, Pediatrics, 130, e1720, 10.1542/peds.2012-1384 Bredemeier, 2012, One-year clinical and radiological evolution of a patient with refractory Takayasu′s arteritis under treatment with tocilizumab, Clin Exp Rheumatol, 30, S98 Canas, 2014, Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis, J Clin Rheumatol, 20, 125, 10.1097/RHU.0000000000000098 de Kruif, 2012, Streptococcal lung abscesses from a dental focus following tocilizumab: a case report, Clin Exp Rheumatol, 30, 951 Goel, 2013, Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis, Int J Rheum Dis, 16, 754, 10.1111/1756-185X.12220 Loricera, 2014, Tocilizumab in refractory aortitis: study on 16 patients and literature review, Clin Exp Rheumatol, 32, S79 Mekinian, 2015, Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients, Circulation, 132, 1693, 10.1161/CIRCULATIONAHA.114.014321 Nishimoto, 2008, Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody, Arthritis Rheum, 58, 1197, 10.1002/art.23373 Salvarani, 2012, Tocilizumab: a novel therapy for patients with large-vessel vasculitis, Rheumatology (Oxford), 51, 151, 10.1093/rheumatology/ker296 Salvarani, 2012, Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers, Clin Exp Rheumatol, 30, S90 Schiavon, 2014, Takayasu arteritis and NYHA III/IV idiopathic cardiomiopathy: tocilizumab proves effective and safe, Joint Bone Spine, 81, 278, 10.1016/j.jbspin.2013.11.008 Seitz, 2011, Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series, Swiss Med Wkly, 141, w13156 Unizony, 2012, Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica, Arthritis Care Res, 64, 1720, 10.1002/acr.21750 Xenitidis, 2013, Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis, Rheumatology (Oxford), 52, 1729, 10.1093/rheumatology/ket107 Youngstein, 2014, Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-alpha and IL-6 receptor targeted therapies in refractory Takayasu arteritis, Clin Exp Rheumatol, 32, S11 Clifford, 2014, Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies, Curr Opin Rheumatol, 26, 7, 10.1097/BOR.0000000000000004 Osman, 2014, The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis, PloS One, 9, e115026, 10.1371/journal.pone.0115026 Arita, 2015, Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis, Int J Cardiol, 187, 319, 10.1016/j.ijcard.2015.03.399 Dagna, 2011, Pentraxin-3 as a marker of disease activity in Takayasu arteritis, Ann Int Med, 155, 425, 10.7326/0003-4819-155-7-201110040-00005 Matsuyama, 2003, Matrix metalloproteinases as novel disease markers in Takayasu arteritis, Circulation, 108, 1469, 10.1161/01.CIR.0000090689.69973.B1 Noguchi, 1998, Increased levels of soluble forms of adhesion molecules in Takayasu arteritis, Int J Cardiol, 66, S23, 10.1016/S0167-5273(98)00145-4 Noris, 1999, Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?, Circulation, 100, 55, 10.1161/01.CIR.100.1.55 Aydin, 2015, Outcome measures for Takayasu’s arteritis, Curr Opin Rheumatol, 27, 32, 10.1097/BOR.0000000000000129 Brunner, 2010, Takayasu arteritis in children and adolescents, Rheumatology (Oxford), 49, 1806, 10.1093/rheumatology/keq167 Cakar, 2008, Takayasu arteritis in children, J Rheumatol, 35, 913 Eleftheriou, 2015, Vasculitis in children, Nephrol Dial Transplant, 30, i94 Morales, 1991, Takayasu’s arteritis in children, J Rheumatol, 18, 1081 Park, 2005, Clinical characteristics and outcomes of Takayasu’s arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification, Scand J Rheumatol, 34, 284, 10.1080/03009740510026526